Monte Rosa Therapeutics, Inc. (GLUE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Monte Rosa Therapeutics, Inc. (GLUE)

Company Performance

Current Price

as of Oct 16, 2024

$5.50

P/E Ratio

N/A

Market Cap

$337.55M

Description

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Metrics

Overview

HQBoston, MA
SectorHealth Technology
IndustryBiotechnology
TickerGLUE
Price$5.5+7.42%

Trading Information

Market Cap$337.55M
Float72.65%
Average Daily Volume (1m)630,093
Average Daily Volume (3m)353,264
EPS-$2.24

Company

Revenue$5.76M
Rev Growth (1yr)N/A
Net Income-$30.31M
Gross Margin56.12%
EBITDA Margin-651.37%
EBITDA-$30.58M

EV$48.57M
EV/Revenue8.43
P/EN/A
P/S68.03
P/B1.50

Documents

Factset Street Account

Monte Rosa Therapeutics reports Q3 EPS ($0.70) vs FactSet ($0.72) [8 est, ($0.78)-(0.58)] ($3.69, 0.00) (2023-11-09T12:19:22Z)

Monte Rosa Therapeutics presents preclinical MRT-6160 data at ACR Convergence 2023 ($3.42, +0.10) (2023-11-07T15:01:50Z)

Monte Rosa Therapeutics announces interim data from Phase 1/2 trial of MRT-2359; conference call today at 8:00 ET ($5.00, 0.00) (2023-10-17T11:11:37Z)

Monte Rosa Therapeutics announces collaboration with Roche ($5.00, 0.00) (2023-10-17T11:07:20Z)

Monte Rosa Therapeutics announces $25M registered direct offering priced at the market ($2.50, 0.00) (2023-10-26T20:33:57Z)